# Low Dose Olanzapine to the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy in Children and Adolescents

> **NCT05346731** · PHASE3 · UNKNOWN · sponsor: **Federal Research Institute of Pediatric Hematology, Oncology and Immunology** · enrollment: 210 (estimated)

## Conditions studied

- Chemotherapy-induced Nausea and Vomiting

## Interventions

- **DRUG:** Ondansetron
- **DRUG:** Dexamethasone
- **DRUG:** Aprepitant
- **DRUG:** Olanzapine

## Key facts

- **NCT ID:** NCT05346731
- **Lead sponsor:** Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-01
- **Primary completion:** 2024-03
- **Final completion:** 2024-08
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2022-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05346731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05346731, "Low Dose Olanzapine to the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy in Children and Adolescents". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05346731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*